Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
149.06
+4.49 (3.11%)
At close: Oct 31, 2025, 4:00 PM EDT
152.04
+2.98 (2.00%)
After-hours: Oct 31, 2025, 6:20 PM EDT
Repligen Market Cap
Repligen has a market cap or net worth of $8.39 billion as of October 31, 2025. Its market cap has increased by 8.37% in one year.
Market Cap
8.39B
Enterprise Value
8.36B
1-Year Change
8.37%
Ranking
Category
Stock Price
$149.06
Market Cap Chart
Since December 1, 1998, Repligen's market cap has increased from $28.10M to $8.39B, an increase of 29,742.56%. That is a compound annual growth rate of 23.56%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 31, 2025 | 8.39B | 3.98% |
| Dec 31, 2024 | 8.06B | -19.67% |
| Dec 29, 2023 | 10.04B | 6.78% |
| Dec 30, 2022 | 9.40B | -35.80% |
| Dec 31, 2021 | 14.64B | 45.21% |
| Dec 31, 2020 | 10.08B | 109.40% |
| Dec 31, 2019 | 4.82B | 108.18% |
| Dec 31, 2018 | 2.31B | 46.35% |
| Dec 29, 2017 | 1.58B | 51.58% |
| Dec 30, 2016 | 1.04B | 11.88% |
| Dec 31, 2015 | 932.00M | 43.85% |
| Dec 31, 2014 | 647.90M | 48.87% |
| Dec 31, 2013 | 435.20M | 122.72% |
| Dec 31, 2012 | 195.40M | 83.30% |
| Dec 30, 2011 | 106.60M | -26.18% |
| Dec 31, 2010 | 144.40M | 14.24% |
| Dec 31, 2009 | 126.40M | 7.21% |
| Dec 31, 2008 | 117.90M | -41.78% |
| Dec 31, 2007 | 202.50M | 137.12% |
| Dec 29, 2006 | 85.40M | -29.07% |
| Dec 30, 2005 | 120.40M | 39.03% |
| Dec 31, 2004 | 86.60M | -33.64% |
| Dec 31, 2003 | 130.50M | 57.04% |
| Dec 31, 2002 | 83.10M | 28.04% |
| Dec 31, 2001 | 64.90M | -27.65% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 772.59B |
| Johnson & Johnson | 455.04B |
| AbbVie | 385.18B |
| UnitedHealth Group | 309.40B |
| AstraZeneca | 253.98B |
| Novartis AG | 237.13B |
| Novo Nordisk | 216.87B |
| Abbott Laboratories | 214.96B |